Moderation of treatment outcomes by polygenic risk for alcohol‐related traits in placebo‐controlled trials of topiramate
These findings provide proof of principle for the use of alcohol-related PGS as moderators of the effects of topiramate for treating AUD. Larger RCTs of topiramate are needed to provide adequate statistical power to validate this pharmacogenetic approach to precision AUD treatment.
Authors
- Christal N. Davis (ORCID: https://orcid.org/0000-0003-3974-5598)
- Joel Gelernter (ORCID: https://orcid.org/0000-0002-4067-1859)
- Joanna M. Biernacka (ORCID: https://orcid.org/0000-0001-9350-4440)
- Rachel L. Kember (ORCID: https://orcid.org/0000-0001-8820-2659)
- Richard Feinn (ORCID: https://orcid.org/0000-0002-4158-7640)
- Henry R. Kranzler (ORCID: https://orcid.org/0000-0002-1018-0450)
- Zeal Jinwala (ORCID: https://orcid.org/0009-0005-5062-0827)
- Heng Xu (ORCID: https://orcid.org/0000-0003-1307-4896)
- Hang Zhou (ORCID: https://orcid.org/0000-0002-2616-923X)
Institutions
- Mayo Clinic (US)
- Yale University (US)
- VA Connecticut Healthcare System (US)
- Philadelphia VA Medical Center (US)
- Connecticut Health Foundation (US)
- Mayo Clinic in Florida (US)
- Quinnipiac University (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Alcohol Clinical and Experimental Research
- Published
- 2025-05-30
- DOI
- https://doi.org/10.1111/acer.70052
- Citations
- 1
- Primary Topic
- Genetic Associations and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- U.S. Department of Veterans Affairs
- National Institute on Alcohol Abuse and Alcoholism